Instil Bio TIL 深 沪
已收盘 07-02 16:00:00 美东时间
7.73
+0.040
+0.52%
华盛通- 最 高7.99
- 今 开7.82
- 成交量 6841股
- 最 低 7.69
- 昨 收 7.69
- 总市值 5242.47万
- 52周最高 33.833
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 5.67
- 委 比 18.34%
- 总股本 678.20万
- 历史最高 589.80
- 量 比 0.38
- 振 幅 3.90%
- 历史最低 0.80
- 每 手 1
- 风险率 7.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics announced that Dr. David Chang will transition from CEO to continue serving on the Board of Directors. Dr. Zachary Roberts, currently EVP, R&D and CMO, will succeed him as President and CEO effective July 1, 2026. Dr. Chang's leadership established Allogene as a leader in allogeneic CAR T therapies, advancing innovative treatments and infrastructure. Dr. Roberts has reshaped the company's clinical strategy, driving advanceme...
05-28 21:02
Instil Bio Non-GAAP EPS of -$0.32
Instil Bio press release (TIL): Q1 Non-GAAP EPS of -$0.32. As of March 31, 2026, Instil had approximately $74.7 million in total cash, cash equivalents, restricted cash and marketable securities, whic...
05-15 19:12
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio reported its Q1 2026 financial results, highlighting a cash position of $74.7 million, enabling operations beyond 2027. The company is evaluating acquisitions and in-licensing opportunities to expand its pipeline. Q1 expenses included $0.7 million in R&D, $5.3 million in G&A, and $1.0 million in restructuring charges. Net loss per share was $0.62, improving from $4.32 in Q1 2025. CEO Bronson Crouch emphasized strategic progress and fin...
05-15 11:00
Instil Bio replaces Deloitte with RSM as independent auditor for fiscal 2026
Instil Bio replaces Deloitte with RSM as independent auditor for fiscal 2026 Instil Bio named RSM US as independent registered public accounting firm for fiscal 2026, replacing Deloitte effective April 1, 2026. Deloitte audit reports for 2025 and 2024 carried no adverse opinion or disclaimer. No acc
04-03 20:01
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Instil Bio Q4 net loss per share narrows
Instil Bio Q4 net loss per share narrows Overview U.S. biotechnology firm's Q4 net loss per share narrowed from prior year Company ended 2025 with $76.3 mln in cash and marketable securities, expects runway beyond 2027 Instil discontinued AXN-2510 development, now pursuing acquisitions and in-licens
03-27 19:09
Instil Bio Q4 Adj. EPS $(0.97) Beats $(2.03) Estimate
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(2.03) by 52.15 percent. This is a 10.19 percent increase over losses of $(1.08) per share from the
03-27 19:08
Instil Bio FY2025 operating loss widens 6.85% to $(78.6) million; revenue rises 110.17% to $9.0 million
Instil Bio FY2025 operating loss widens 6.85% to $(78.6) million; revenue rises 110.17% to $9.0 million Instil Bio published an annual report on Form 10-K with full-year financial results, reporting a net loss of USD 71.4 million. Total operating expenses were USD 78.6 million, including research an
03-27 19:07
Instil Bio Non-GAAP EPS of -$0.97 beats by $2.81
Instil Bio press release (TIL): Q4 Non-GAAP EPS of -$0.97 beats by $2.81. As of December 31, 2025, Instil had $76.3 million in total cash, cash equivalents, restricted cash and marketable securities, ...
03-27 19:04
